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Abstract
Purpose To compare the clinical outcomes of bone-
patellar tendon-bone (BTB) allografts processed via a
novel sterilization system with the traditional aseptically
processed BTB allografts for anterior cruciate ligament
(ACL) reconstruction.
Methods A total of 67 patients undergoing ACL recon-
struction at 6 independent investigation sites were
randomized into one of two intervention groups, Bio-
Cleanse-sterilized or aseptic BTB allografts. Inclusion
criteria included an acute, isolated, unilateral ACL tear,
and exclusion criteria included prior ACL injury, multi-
ligament reconstruction, and signs of degenerative joint
disease. Post-op examiners and patients were blinded to
graft type. Patients were evaluated at 6, 12, and 24 months.
Clinical outcomes were compared using the IKDC, a
KT-1000 knee arthrometer, level of effusion, and ranges of
motion (ROM).
Results After randomization, 24 patients received aseptic
BTB allografts and 43 patients received BioCleanse-ster-
ilized allografts. Significant improvement in IKDC scores
(P \ 0.0001) as well as KT-1000 results (P \ 0.0001) was
noted over the 24-month period for both groups. IKDC or
KT-1000 results were not significantly different between
groups at any time point. Active flexion ROM significantly
improved from pre-op to 24-month follow-up (P \ 0.0001)
with no difference between groups at any time point.
Active extension ROM did not differ significantly between
the two groups.
Conclusions These results indicate that the sterilization
process, BioCleanse, did not demonstrate a statistical dif-
ference in clinical outcomes for the BTB allograft at
2 years. The BioCleanse process may provide surgeons
with allografts clinically similar to aseptically processed
allograft tissue with the benefit of addressing donor-to-
recipient disease.
Level of evidence II.
Keywords Anterior cruciate  Allograft  Sterilized 
Outcomes  IKDC
Introduction
In anterior cruciate ligament (ACL) reconstruction, the
choice of graft has been an area of debate for several years.
While there are arguments made that autograft is the gold
standard [6, 40], the use of allografts is relatively common
with successful outcomes having been well documented in
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the literature. The use of allograft tissue has been noted to
decrease operating time, eliminate donor site morbidity,
and increase the tissue available for multi-ligament cases
[24, 42]. Clinical studies that evaluated outcomes reported
positive results for chronic ligamentous laxity [23].
Subsequently, there have been a number of reports of
successful outcomes using allografts in surgery [7, 15, 16].
Further support for the use of allografts can be seen in
long-term studies which have reported positive results for
patients as long as 10 years after surgery [1, 20, 23]. With
the prospect of increased morbidity associated with auto-
graft procedures [2, 12, 43], the rationale for allograft use
in ACL surgery seems warranted.
One disadvantage which has received a great deal of
attention is that disease can be transmitted as a result of the
allograft. Use of allograft tissue has historically been
associated with HIV and HCV transmission along with
bacterial infections, resulting in significant morbidity and
mortality [5]. These risks can be minimized by rigorous
donor screening, aseptic harvesting techniques, and tissue
processing, but the allograft that is only aseptically pro-
cessed cannot be guaranteed to be free of all viruses or
bacterial spores.
Historically, multiple sterilization techniques have been
used for allograft tissue, most notably gamma irradiation
and ethylene oxide. The use of gamma irradiation and
ethylene oxide has decreased over time in favour of less
destructive and biologically friendly chemical cleaning
processes [18, 26, 27, 30, 36, 38, 39, 42].
The BioCleanse tissue sterilization process (RTI
Biologics, Alachua, FL) is a non-thermal combination of
mechanical and chemical processes that has been reported
to inactivate or remove all sources of infectious disease
transmission while not compromising the biomechanical
and physiological properties of allograft bone and soft
tissue [21, 22, 29, 34]. To date, there has not been a direct
comparison of clinical outcomes via a randomized, pro-
spective clinical trial with this type of sterilized allograft.
The purpose of this study was to compare the clinical
outcomes of patients who underwent ACL reconstruction
with BioCleanse BTB allografts to those who received the
traditional aseptically, non-irradiated processed BTB allo-
grafts. It was hypothesized that patients undergoing ACL
reconstruction with BioCleanse BTB allografts would not
have statistically or clinically meaningful differences in
outcomes from patients who received non-irradiated asep-
tically processed BTB allografts.
Materials and methods
Patients who presented with an acute (\4 months), isolated
ACL rupture were asked to participate in this study. The
patients were at one of 6 independent research sites. A total
of 67 patients were randomly assigned, to 1 of 2 groups
using the ranblock.exe application, and received either the
BioCleanse or aseptic BTB allograft. The mean age of all
patients was 34 (SD 9) years. Patients requiring multi-
ligament reconstruction, moderate to severe concomitant
meniscal repair or ACL revision surgery were excluded.
This study was approved by the Institutional Review Board
(or equivalent) at all the participating sites and all subjects
gave informed consent.
Aseptic grafts were obtained from one of 3 tissue banks
currently providing BTB allografts in the United States. All
donors were screened, and all tissues were harvested and
processed according to standards set forth by the American
Association of Tissue Banks [3]. Each investigational site
chose their own supplier for the aseptic grafts.
The BioCleanse tissue sterilization system uses a com-
bination of mechanical and chemical processes, working in
conjunction with each other. The mechanical component
applies oscillating positive and negative pressure in the
presence of the chemical agents (including detergents and
sterilants), which perfuse the tissue. This combination
removes blood and lipids and inactivates or removes
pathogenic microorganisms. Repeated rinses throughout
the process remove debris, and final rinses remove residual
chemicals, leaving the tissue biocompatible [42].
All patients underwent single incision arthroscopic ACL
reconstruction under general anaesthesia. A tourniquet was
used in every case. All articular damage was noted and
recorded using the Outer-bridge classification system. In
addition, all meniscal damage was identified, and lesions
were treated with partial menisectomy. Following this, a
guide system was used that placed the tibial tunnel centre
at the anatomical centre of the native ACL. The femoral
tunnel was drilled just anterior to the over the top position
at the ‘2AM/10PM’ isometric single bundle location using
the standard transtibial approach. An endoscopic femoral
aimer was used to minimize patient to patient variability.
The grafts were reconstituted using room temperature sal-
ine for a minimum of 10 min. The BioCleanse grafts were
preshaped with a 10 mm diameter and 25–30 mm length
bone blocks. The aseptic grafts were shaped individually in
each centre during surgery to the same dimensions as the
BioCleanse preshaped grafts. The graft was then pulled
distal to proximal via the tibial tunnels. Both femoral and
tibial fixations were achieved using metallic interference
screws. After fixation at the femur, the graft was tensioned
with approximately 20 lbs of force for tibial fixation at near
extension. Following this, the knee was put through a full
range of motion to verify that there was no graft
impingement. Stability was then checked to make sure that
both the anterior drawer sign and the pivot shift were
eliminated. At this point, the arthroscopic instruments were
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removed and the distal tibial incision was closed in a
standard fashion.
All patients followed a uniform ACL rehabilitation
protocol. Following surgery, the patients began a therapist-
directed physical therapy programme. Post-operative
rehabilitation programmes emphasized range of motion
restoration, quadriceps strengthening, and patellofemoral
joint protection. These were divided into 6 phases using
objective criteria for advancement to the next phase; these
phases took up to 6 months to complete.
At 3, 6, 12, and 24 months post-operatively, the patients
returned to their respective clinics for an evaluation
including the International Knee Documentation Commit-
tee (IKDC) form along with a physical examination for
range of motion (ROM) effusion and a KT-1000 knee
arthrometer test. All sites received a training DVD dem-
onstrating KT-1000 testing to ensure standard and consis-
tent use when evaluating the ACL at maximum manual
testing. Previous research has shown KT-1000 testing to be
reliable and repeatable [14, 25, 28]. Both the examiner and
the patient were blinded as to the type of graft implanted.
Statistical analysis
The IKDC scores, KT-1000 measures, and ROM were
compared using a repeated-measures ANOVA. A chi-
square test and Fisher’s exact test were used to compare
between categorical variables, that is, gender distribution
and grade of effusion. Demographic characteristics were
compared using a Student’s t test. An a priori power anal-
ysis was primarily based on KT-1000 measures. Using G3
software (Heinrich Heine University Du¨sseldorf, Germany)
with an effect size of 0.33, alpha of 0.05, power of 0.80, for
3 groups (aseptic, gamma-irradiated, and BioCleanse
grafts), we estimated that 112 patients would be required.
Due to circumstances such as surgeon preference and
patient recruitment, the gamma-irradiated BTB allograft
group was dropped. This left the aseptic and BioCleanse
grafts for the final analysis. The initial statistical plan had
been an unbalanced design, allowing for an unequal number
of patients in each group. The level of significance for all
statistical tests was set at an alpha level of 0.05.
Results
As shown in Table 1, there was no significant difference
between the groups for age, body mass index, or gender
distribution. Of the 43 patients enrolled in the BioCleanse
group, there were 29, 24, 20, and 18 tested at 3, 6, 12, and
24 months, respectively. For the aseptic group, testing was
completed on 23, 20, 13, and 10 patients at 3, 6, 12, and
24 months, respectively.
The data for IKDC scores are presented in Fig. 1. The
mean IKDC pre-operatively was 51 (95 % CI 42.3–53.8)
and 48 (95 % CI 42.3–53.8) for the aseptic and BioCleanse
groups, respectively. This improved over the 24 months to
89 (95 % CI 81.2–96.4) for the aseptic group and 88 (95 %
CI 80.6–95.4) for the BioCleanse group. There was no
statistically significant difference in IKDC scores at any
time point measured.
Similarly, the KT-1000 measurements steadily improved
over time, from a mean of 4.6 mm (95 % CI 3.7–6.1) and
4.3 mm (95 % CI 3.3–5.3) for the aseptic and BioCleanse
groups, respectively. At the end of the study, the anterior
knee displacement as measured by the KT-1000 was
recorded at 1.6 mm (95 % CI 1.1–2.1) and 1.5 mm (95 %
CI 0.9–2.1) for aseptic and BioCleanse groups, respectively
(Fig. 2). No statistically significant difference in KT-1000
scores was found between the groups at any time point.
The results for range of motion (ROM) showed no
significant differences between groups at any time point.
This was true for the active flexion ROM (Fig. 3) as well as
the deficit for passive extension, measured between ipsi-
lateral and contralateral legs. Effusion grading showed no
significant differences between the groups. There were no
complications noted at 24 months.
There were no cases of either disease transmission or
infection that could be attributed to the grafts. This was
true for both aseptic and BioCleanse grafts.






Age (years) 31.3 ± 9.2 35.6 ± 8.9 ns
Body mass index 26.7 ± 4.8 26.8 ± 4.7 ns
Revision surgeries 1 1 ns
Male (n) 16 25 ns
Female (n) 8 18
Fig. 1 The IKDC scores for the 2 groups. There were no statistically
significant differences between the 2 groups at any time point
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Discussion
This prospectively evaluated clinical outcomes study
compared aseptically processed allografts to those treated
through the BioCleanse sterilization process. While there
have been reports comparing outcomes of irradiated
allografts to autografts as well as aseptic allografts, the
functional outcomes using BTB grafts that have been
chemically, non-thermally sterilized have not been reported
in the literature. It should be noted that ‘aseptic’ processing
does not necessarily mean that the tissue is free of viruses,
bacteria, and/or spores. The possibility of contamination
coming from the donor cannot be eliminated and could be
inherent to the graft [4], which is why tissue banks attempt
to clean with different chemical processes.
A number of clinical studies have been published
[13, 15, 19, 22, 32, 35, 37, 38] which compared allografts
and autografts in ACL reconstruction. A recent meta-
analysis demonstrated no clinical difference when Level I
studies were analysed [11]. This study attempted a stan-
dardized single bundle, isocentric, anatomical footprint
ACL reconstruction for each surgical site to try and ensure
consistency within the study.
These results show comparable outcomes between
aseptically processed allografts and those that have been
sterilized using the BioCleanse process. The importance of
this lies in the reduction in the risk of disease transmission
which has been documented [5]. Although appropriate
donor screening and aseptic harvesting techniques can
reduce the risk [17, 33], a method of sterilization that does
not damage the structural integrity of the graft is essential.
The BioCleanse process inactivates or removes sources of
infectious disease transmission without compromising
structural integrity of allograft bone and soft tissue [29,
34]. Validation tests of the process have indicated a ste-
rility assurance level of 10-6 [18]. The FDA also states that
a sterility assurance level of 10–6 is necessary for all
devices unless there is substantial justification why this
level cannot be achieved [43]. An important difference
between BioCleanse and other sterilization processes is
that BioCleanse does not use irradiation, ethylene oxide, or
excessive heat, all of which may adversely impact the
properties of the graft tissue [8–10, 26, 36, 41].
There are some limitations to this study. While it may be
pointed out that the number of sites may affect reliability,
previous literature has pointed to the high intertester reli-
ability when using the KT-1000 [25], and that examiner
experience can improve the precision and reliability when
using multiple sites [31]. Considering the years of experi-
ence of the principal investigators, we expect that the
reliability between sites would be high. Statistically, an
improved power would make the results more certain.
Although 67 patients were initially enrolled in this
study, the loss to follow-up resulted in only 18 patients in
the BioCleanse group and 10 in the aseptic group at
24 months, which reduced the statistical power in the
study. The difference in group sizes had been anticipated in
the initial statistical plan for an unbalanced design, yet the
diminishing numbers did impact power. It should be noted
that the loss of patients to follow-up did affect the power of
the final statistical analysis, with the power of the KT
analysis calculated to be 0.75, while the power of the IKDC
test was calculated to be 0.52.
Also, although the same surgical technique and reha-
bilitation protocol were applied for all patients at all sites,
the role of individual technique as well as adherence to
rehabilitation guidelines can introduce variance in the
results.
Lastly, while we had initially attempted to compare
BioCleanse, aseptic, and gamma-irradiated allografts,
extremely low enrolment in the gamma-irradiated arm
prevented an adequate statistical comparison. This was due
to a general shift away from irradiated allografts and was
coupled with several patients who declined to participate in
this study when they were informed they might receive an
irradiated graft.
Fig. 2 The mean KT-1000 side-to-side differences for anterior
displacement at four time points. No significant differences were
found between groups
Fig. 3 Mean active flexion range of motion for the treated knee for
both groups
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Conclusions
All patients, whether receiving BioCleanse BTB allografts
or aseptically processed BTB allografts, exhibited similar
clinical outcomes. There were no complications, with only
one revision required in each group. This short-term data
shows that the BTB allografts processed through the Bio-
Cleanse process provide a viable option for ACL recon-
struction while minimizing the risk of disease transmission.
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